87 results about "Vasospasm" patented technology

The present invention relates to devices and systems that alter intracranial compliance, cerebral blood flow and/or intracranial pressure pulsatility/waveform by oscillating the contraction and expansion of a compressible composition within the cranial or spinal cavities such that they increase intracranial capacity. The contraction and expansion of the compressible composition in the oscillating compliance devices can be due to an individual's intracranial pressure, the result of the expansion and compression of a reservoir which is mediated by the contractility of the heart or driven by a pump gaited to a biorhythm. The invention also relates to methods for protecting an individual's brain from abnormal arterial pulsations and for altering an individual's cerebral blood flow using the devices and systems of the invention. The oscillating compliance devices can be used to treat several diseases and/or conditions characterized by altered/abnormal intracranial compliance, cerebral blood flow and/or intracranial pressure pulsatility/waveform, including hydrocephalus, stroke, dementia and migraine headaches, vasospasms, congestive heart failure, cardiopulmonary bypass or carotid endarterectomy.

The invention discloses a thrombus extraction support device. The thrombus extraction support device comprises a thrombus extraction support, a conveying guide wire, a guiding guide wire and marking rings, and is characterized in that the thrombus extraction support is composed of a front thrombus extraction support body and a back thrombus extraction support body; the marking rings include the middle-section marking ring and the near-end marking ring, the back end of the front thrombus extraction support body is fixedly connected with the back thrombus extraction support body through the middle-section marking ring, and the front end of the front thrombus extraction support body is fixedly connected with the guiding guide wire so that vascular irritation of the front thrombus extraction support body can be effectively reduced, and vasospasm in the thrombus extraction process can be prevented; the back end of the back thrombus extraction support body is fixedly connected with the near-end marking ring, the front end of the conveying guide wire is connected with the near-end marking ring, and the back end of the conveying guide wire is connected with a microtubule so that the front thrombus extraction support body and the back thrombus extraction support body can successively carry out thrombus extraction, and thrombus can be effectively prevented from falling in blood vessels. Due to the structure, the thrombus extraction support device has the advantages that the structure is simple, the capturing performance is high, thrombus extraction is complete, vasospasm is prevented, and the blood flow recovering velocity is high.

The invention relates to methods and products for treatment of hypertension, high blood pressure and vasospasm. Specifically, TRPC3 channel inhibitors and related compositions and kits are described.

The invention belongs to the field of medicament technology, and especially relates to applications of a tetramethylpyrazine derivative tetramethylpyrazine nitrone to medicament preparation as well as prevention and treatment of brain injury diseases. Experiments prove that tetramethylpyrazine nitrone can improve traumatic brain injury and brain injury after subarachnoid hemorrhage; the improvements concretely comprise the following aspects: improvement of behaviors of model rats with traumatic brain injury and subarachnoid hemorrhage, reduction of cerebral infarction areas due to traumatic brain injury, improvement of vasospasm state after subarachnoid hemorrhage, and protection of brain tissues. Mechanisms of action of tetramethylpyrazine nitrone relate to inhibition of oxidative stress injuries, inhibition of inflammatory reactions, and apoptosis resistance. Tetramethylpyrazine nitrone can be used as a medicine for preventing and treating brain injury diseases, especially traumatic brain injury and subarachnoid hemorrhage, and can be prepared into various dosage forms with medicinal carriers.

The invention is directed to nonpeptide substituted benzodiazepines of Formula I,

wherein A, X, n, R¹, R², R³, R⁴, R⁵, a and b are as described in the specification, which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased vascular resistance and cardiac insufficiency. Pharmaceutical compositions comprising a compound of Formula I and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure, cerebral edema and ischemia, stroke, thrombosis, or water retention are also disclosed.

The invention relates to a medicament for curing coronary heart diseases. The medicament is a preparation which comprises the following crude drugs by the weight part: 8 to 16 parts of Chinese angelica root, 9 to 19 parts of hoantchy root, 9 to 18 parts of ligusticum wallichii, 9 to 18 parts of red-rooted salvia root, 8 to 16 parts of Chinese thorowax root, 9 to 18 parts of glossy privet fruit, 9 to 18 parts of scrophulariaceae canaria, 9 to 18 parts of eucommia bark, 3 to 6 parts of aloe and 4 to 8 parts of antifebrile dichroa. The formula of the medicament focuses on the regulation of kidney functions, and at the same time, attaches importance to the coordination of functions of internal organs, such as the kidney, the heart, the liver, the spleen, etc. The medicament can not only reduce blood lipid, resist coagulation, reduce blood viscidity and dissolve internal clot, but also improve the functions of blood vessel endothelium. Furthermore, the medicament can remove vasospasm, resist arteriosclerosis and stabilize vulnerable plaque, and have double curative effects on blood diseases and vascular diseases, thereby effectively curing the cardiovascular system diseases.

The invention provides medicine for treating cardiovascular and cerebrovascular diseases. The medicine is glycoprotein, mixture of polysaccharide and protein, polypeptide or protein. The medicine has the advantages that the triglyceride and total cholesterol contents of rats can be lowered effectively; the anoxia survival time of mice can be prolonged to reach 70-85 minutes; the microcirculation can be improved, the coronary artery can be expanded, the myocardial blood supply can be improved, the blood flow of the brain and the coronary artery can be increased, the heart rate can be reduced, and the myocardial oxygen consumption index can be lowered to improve myocardial blood metabolism, resist thromboxane, increase high-density lipoprotein, resist vasospasm and reduce platelet aggregation, and the total cholesterol and triglyceride of the blood can be lowered; the medicine is safe, efficient and free of side effect.

The present invention relates to amino butanetriol aescin and its isomer for relieving swelling, diminishing inflammation and improving blood circulation. The amino butanetriol aescin is prepared with amino butanetriol and aescin, and has the structural formula as shown. The amino butanetriol aescin has high water solubility, lowered possibility of resulting in vasospasm and raised administrating safety.

The invention provides a method for establishing a coronary artery microvascular spasm pig-model, and belongs to the technical field of medical models. The method comprises that after bilateral femoral arteries of a test pig are free, distal ends of the femoral arteries are ligatured by wires, a left-side sheathing canal is fed into a pigtail catheter, blood flow dynamics indexes are determined, in a right-side sheathing canal, a coronary artery radiography process is carried out so that the middle of an anterior descending branch is displayed, and a neuropeptide Y is injected into the coronary artery so that the coronary artery microvascular spasm pig-model is obtained. The coronary artery microvascular spasm pig-model has good singularity, well fits to the clinical disease fact, satisfies clinical psychological stress characteristics, can be operated simply, is scientific and reasonable, has short modeling time, small damage and low animal mortality, realizes coronary artery microvascular evaluation on the carrier, realizes qualitative and quantitative evaluation of microvascular spasm state and degree, realizes real-time observation, provides a novel research means for basic clinical research and is suitable for popularization application.

Novel polymorphic forms of bosentan and processes for their preparation are disclosed. Further, pharmaceutical compositions comprising said polymorphic forms and the use of said compositions in the treatment of patients suffering from endothelin receptor mediated disorders, for example, cardiovascular disorders such as hypertension, pulmonary hypertension, ischemia, vasospasm and angina pectoris are disclosed.

The invention discloses application of anisodine hydrobromide in preparing medicines for preventing or treating depression, in order to develop a medicine for effectively preventing or treating depression. Anisodine has the chemical formula of C17H21NO5 and a relative molecular weight of 319.35, is a pyrethroid type alkaloid, is present in belladonna plants and is a choline receptor blocking agent isolated firstly in China. The hydrobromide of the anisodine is mainly used clinically, and can be used for treating vascular headache, retinal vasospasm, central retinopathy, ischemic optic neuropathy, acute paralysis, paralysis agitans, bronchial asthma, kinesia, organic phosphorus pesticide poisoning and the like. However, literatures reporting treatment of depression are not available. In the invention, experiments show that anisodine hydrobromide plays a role in treating depression, and has a very good therapeutic effect in depression symptoms of interest blank, pleasant sensation disappearance, reduced exiting degree, reduced increment of body weight and the like.

This invention relates to methods and systems for providing a prognosis to a subject on developing vasospasm as a results of hemorrhagic event, and compounds and compositions for treatment thereof. Specifically, the invention relates to the use of haptoglobin genotyping in the prognosis of the development of vasospasm following SAH, and antioxidants such as glutathione peroxidase mimetics for treatment.

The described invention provides site-specific sustained release microparticulate formulations containing a therapeutic amount of an L-type voltage gated calcium channel inhibitor, a PLGA polymer comprising from 25% to 50% glycolide, and a hyaluronic acid. A therapeutic amount of the formulation is effective to reduce signs or symptoms of delayed cerebral ischemia comprising one or more of a cortical spreading ischemia, a cortical spreading depolarization, a plurality of microthromboemboli, or an angiographic vasospasm after brain injury in a mammal, while reducing the risk of systemic hypotension, cardiac dysfunction, anoxia, and intracranial hypertension.

A delivery system for sustained release of a calcium-channel blocking agent is adapted for introduction in the cerebrospinal fluid of a subject. The delivery system comprises a solid dispersion product of a calcium-channel blocking agent in a mixture of a (i) first poly(lactide-co-glycolide) having a molecular weight distribution centered around a first number average molecular weight Mn1 and a (ii) second poly(lactide-co-glycolide) having a molecular weight distribution centered around a second number average molecular weight Mn2, wherein Mn1 is in the range of from 2000 to 3000 g/mol and the ratio of Mn1/Mn2 is from 1.8 to 3.5. The delivery system is deposited in the vicinity of or adjacent to a blood vessel showing vasospasm or suspected of developing vasospasm.

A method and solution for perioperatively inhibiting a variety of pain, inflammation, spasm and restenosis processes resulting from cardiovascular or general vascular therapeutic and diagnostic procedures. The solution preferably includes multiple pain and inflammation inhibitory agents and spasm inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. Specific preferred embodiments of the solution of the present invention for use in cardiovascular and general vascular procedures also include anti-restenosis agents. The solution is introduced luminally to continuously irrigate an arterial site during an operative/interventional or diagnostic procedure for preemptive inhibition of pain and inflammation, vascular and non-vascular smooth muscle spasm, and restenosis while avoiding undesirable side effects associated with oral, intramuscular, subcutaneous or intravenous application of larger doses of the agents. One preferred solution to inhibit pain, inflammation, vasospasm and restenosis includes a serotonin2 antagonist, a cyclooxygenase inhibitor, an endothelin antagonist, an ATP-sensitive K<+> channel antagonist, a Ca<2+> channel antagonist, a nitric oxide donor, an anti-thrombin agent, a glycoprotein IIb/IIIa receptor blocker, a PKC inhibitor and a protein tyrosine kinase inhibitor.